BROWSE·page 370 of 611

Browse EX-10 agreements

7,325 matching material contract exhibits.


EX-10.2

Genasys Inc.

FIRST AMENDMENT

TO

WARRANT AGREEMENT

This First Amendment (this “Amendment”) to that certain Warrant Agreement dated as of dated as of May 13, 2024, by and between Genasys Inc., a Delaware corporation, (the “Company”) and Issuer Direct Corporation as warrant agent (together with its successors and assigns, the “Warrant Agent”) (the “Warrant Agreement”) is entered into as of July 13, 2026, 2026 by and between the Company, the Warrant Agent and the undersigned Holders (as defined in the Warrant Agreement)

WHEREAS, pursuant to Section 8.5 of the Warrant Agreement, the Warrant Agreement may be amended, modified or waived pursuant to a written agreement signed by the Warrant Agent and the Company and consented to by the Super-Majority Holders;

WHEREAS, the undersigned Holders constitute the Super-Majority Holders; and

WHEREAS, Company, the Warrant Agent and the undersigned Holders desire to amend certain provisions of the Warrant Agreement, as set forth in greater detail and subject to the terms and conditions outlined in this Amendment.

…

EX-10.2·8-K·CIK 924383·ACC 0001193125-26-304084·Filed Jul 15, 2026, 08:07 ET

EX-10.1

Senti Biosciences Holdings, Inc.

CONTINGENT VALUE RIGHTS AGREEMENT

This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [•], 2026 (this “Agreement”), is entered into by and among Senti Holdings, Inc., a Delaware corporation (“Midco”), and [•] (as the “Rights Agent” (as hereinafter defined)).

RECITALS

WHEREAS, this Agreement is entered into pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of July [•], 2026, by and among Celadon Partners SPV 35, an exempted company incorporated under the laws of the Cayman Islands, Senti Merger Sub, Inc., a Delaware corporation (“Merger Sub”), Senti Biosciences Holdings, Inc., a Delaware corporation (the “Company”), Midco, and Senti Biosciences, Inc., a Delaware corporation (the “Opco”), pursuant to which Merger Sub will be merged with and into Midco (the “Merger”), with Midco continuing as the surviving corporation in the Merger (the “Surviving Corporation”), on the terms and subject to the conditions set forth in the Merger Agreement; and

…

EX-10.1·8-K·CIK 1854270·ACC 0001628280-26-048248·Filed Jul 15, 2026, 07:32 ET

EX-10.1

HYCROFT MINING HOLDING CORP

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (this “Agreement”), dated as of this ______ day of July, 2026, is made by and between Hycroft Mining Holding Corporation, a Delaware corporation (the “Company”) and Michael J. Deal (the “Employee”).

**WHEREAS, **the Company desires to employ the Employee in the capacity Senior Vice President, Chief Operating Officer (SVP, COO); and

WHEREAS, the Company and the Employee have reached agreement concerning the terms and conditions of his employment and wish to formalize that agreement.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this Agreement, the Company and the Employee agree as follows:

…

EX-10.1·8-K·CIK 1718405·ACC 0001493152-26-033283·Filed Jul 15, 2026, 07:05 ET

EX-10.1

Gossamer Bio, Inc.

GOSSAMER BIO, INC. 2019 INCENTIVE AWARD PLAN (As Amended and Restated Effective May 18, 2026) ARTICLE I. PURPOSE The purpose of this amended and restated Plan is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. This Plan constitutes an amendment and restatement of the Gossamer Bio, Inc. 2019 Incentive Award Plan (the “Existing Plan”), effective as of the Restatement Effective Date (as defined below). The Plan was first adopted by the Board on January 12, 2019, and approved by the stockholders of the Company on January 15, 2019, and effective on February 7, 2019 (the “Original Effective Date”), and was most recently amended and restated by the Board on March 24, 2025 and approved by the stockholders of the Company on June 25, 2025. ARTICLE II. ELIGIBILITY Service Providers are eligible to be granted Awards under the Plan, subject to the limitations described he

…

EX-10.1·8-K·CIK 1728117·ACC 0001728117-26-000061·Filed Jul 14, 2026, 20:39 ET

FORM OF DIGITAL ASSET TRADING AGREEMENT

T. Rowe Price Active Crypto ETF

T. ROWE PRICE ACTIVE CRYPTO ETF 8-K

Exhibit 10.1

FORM OF DIGITAL ASSET TRADING AGREEMENT

DIGITAL ASSET TRADING AGREEMENT

This DIGITAL ASSET TRADING AGREEMENT (including all terms, schedules, annexes, supplements and exhibits attached hereto, this “Agreement”), is made and entered into on this 12th day of June, 2026, by and between StoneX Digital LLC, a Florida limited liability company (“StoneX”), and T. Rowe Price Sponsor LLC, acting solely as agent on behalf of Counterparty specified on the signature page hereof (“Counterparty”, and together with StoneX, the “Parties” and each a “Party”).

WHEREAS, the Parties desire to enter into periodic transactions for the purchase and sale of cryptocurrency in accordance with the terms and conditions as set forth herein.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

Article I.
PURCHASE AND SALE OF CRYPTOCURRENCY

…

EX-10.1·8-K·CIK 2089855·ACC 0001999371-26-014983·Filed Jul 14, 2026, 17:31 ET

LIQUIDITY PROVIDER AGREEMENT

T. Rowe Price Active Crypto ETF

T. ROWE PRICE ACTIVE CRYPTO ETF 8-K

Exhibit 10.2

LIQUIDITY PROVIDER AGREEMENT

FOR TRADING IN DIGITAL ASSETS

** **

This LIQUIDITY PROVIDER AGREEMENT FOR TRADING IN DIGITAL ASSETS (this “Agreement”), is made and entered into as of this 15 day of May, 2026, by and between Virtu Financial Singapore Pte. Ltd., (“Liquidity Provider”) and T. Rowe Price Sponsor LLC, (“Sponsor”), acting as agent and not in its individual capacity, on behalf of the Fund (“Counterparty”). Liquidity Provider and Counterparty are each a “Party”, and collectively, the “Parties”.

WHEREAS, the Parties desire to enter into spot purchase or sale transactions in digital assets on a principal to principal basis (each such trade, a “Transaction”);

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

ARTICLE I.

SALE AND PURCHASE OF DIGITAL ASSETS

…

EX-10.2·8-K·CIK 2089855·ACC 0001999371-26-014983·Filed Jul 14, 2026, 17:31 ET

July 8, 2026

Dear Steve:

This revised letter agreement (this “Agreement”) sets forth the terms and conditions of your (referred to as “you” or “your” or “executive”) employment with Longeveron Inc. (the “Company”), which shall be effective as of February 11, 2026 (the “Effective Date”). This Agreement will govern your employment with the Company following the Effective Date on the following terms and conditions:

| |

…

EX-10.1·8-K·CIK 1721484·ACC 0001213900-26-078019·Filed Jul 14, 2026, 17:19 ET

EX-10.1

FIRST BUSEY CORP /NV/

FIRST BUSEY CORPORATION 11440 TOMAHAWK CREEK PARKWAY LEAWOOD, KS 66211 -1- July 13, 2026 Van A. Dukeman At the address on file with the Corporation Dear Van: Reference is made to your Employment Agreement, dated as of December 26, 2001, by and between you and First Busey Corporation (the “Corporation”), as amended from time to time (your “Original Agreement”), and as further amended pursuant to the Letter Agreement between you and the Corporation, dated as of August 26, 2024 (the “Prior Letter Agreement” and, together with your Original Agreement, your “Employment Agreement”). In connection with the Corporation’s ongoing succession planning, you and the Corporation have agreed to extend your expected term serving as Chief Executive Officer of the Corporation and Chief Executive Officer of Busey Bank (the “Bank”) through July 1, 2029 (the “Expected Term”). You will also continue to serve as President of the Corporation, and as Chairman of the Board of Directors of the Corporation and of the Board of Directors of the Bank. This letter agreement confirms to you, and you agree, that your

…

EX-10.1·8-K·CIK 314489·ACC 0000314489-26-000046·Filed Jul 14, 2026, 17:06 ET

EXHIBIT 10.1

Bridgeline Digital, Inc.

BRIDGELINE DIGITAL, INC.

COMMON STOCK 

SALES AGREEMENT

July 14, 2026

WestPark Capital, Inc.

1800 Century Park East, Suite 220

Los Angeles, CA 90067

Ladies and Gentlemen:

Bridgeline Digital, Inc. (the “Company”), confirms its agreement (this “Agreement”) with WestPark Capital, Inc. (“WestPark”), as follows:

1.      Issuance and Sale of Placement Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through WestPark, shares (the “Placement Shares”)* *of the Company’s common stock, $0.001 par value per share (the “Common Stock”); *provided however, *that in no event shall the Company issue or sell through WestPark such number of Placement Shares that (a) exceeds the number of shares or dollar amount of Common Stock registered on the effective Registration Statement (as defined below) pursuant to which the offering is being made, (b) exceeds the number of shares or dollar amount registered on the Prospectus Supplem

…

EX-10.1·8-K·CIK 1378590·ACC 0001437749-26-023553·Filed Jul 14, 2026, 17:01 ET

EXHIBIT 10.2

Anika Therapeutics, Inc.

CONSENT AND FOURTH AMENDMENT TO CREDIT AGREEMENT

THIS CONSENT AND FOURTH AMENDMENT TO CREDIT AGREEMENT (this“Agreement”), dated as of October 30, 2024 (the “SOFR Amendment Effective Date”), is entered into by BANK OF AMERICA, N.A., as administrative agent (the “Administrative Agent”).

RECITALS

WHEREAS, ANIKA THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the Subsidiary Guarantors party thereto, the lenders from time to time party thereto (the “Lenders”), and Bank of America, N.A., as Administrative Agent, have entered into that certain Credit Agreement, dated as of October 24, 2017 (as amended by that certain First Amendment to Credit Agreement, dated as of August 13, 2019, as further amended by that certain Second Amendment to Credit Agreement and First Amendment to Security Agreement, dated as of May 14, 2020, that certain Third Amendment to Credit Agreement, dated as of November 12, 2021 (as amended, modified, extended, restated, replaced, or supplemented fromtime to time, the “Credit Agreement”);

…

EX-10.2·8-K·CIK 898437·ACC 0001171843-26-004635·Filed Jul 14, 2026, 17:00 ET

EXHIBIT 10.1

Anika Therapeutics, Inc.

Execution Version

FIFTH AMENDMENT TO CREDIT AGREEMENT

This FIFTH AMENDMENT TO CREDIT AGREEMENT, dated as of July 10, 2026 (this “Fifth Amendment”), is entered into among ANIKA THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the Subsidiary Guarantors party hereto (if any), each lender party hereto, and the Administrative Agent (as defined below), and modifies that certain Credit Agreement, dated as of October 24, 2017 (as amended by that certain First Amendment to Credit Agreement, dated as of August 13, 2019, as further amended by that certain Second Amendment to Credit Agreement and First Amendment to Security Agreement, dated as of May 14, 2020, as further amended by that certain Third Amendment to Credit Agreement, dated as of November 12, 2021, as further amended by that certain Consent and Fourth Amendment to Credit Agreement (the “Fourth Amendment”), dated as of October 30, 2024, and as may be further amended, restated, amended and restated, extended, supplemented or otherwise modified in writing from time to time and in effect immediately p

…

EX-10.1·8-K·CIK 898437·ACC 0001171843-26-004635·Filed Jul 14, 2026, 17:00 ET

EX-10.3

Research Alliance Corp IV

**PRIVATE PLACEMENT SHARES PURCHASE AGREEMENT **

THIS PRIVATE PLACEMENT SHARES PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this “Agreement”), dated as of July 10, 2026, is entered into by and between Research Alliance Corporation IV, a Cayman Islands exempted company (the “Company”), and Research Alliance Holdings IV LLC, a Cayman Islands limited liability company (the “Purchaser”).

WHEREAS, the Company intends to consummate an initial public offering (the “Public Offering”) of the Company’s Class A ordinary shares, par value $0.0001 per share (each, a “Share”), as set forth in the Company’s Registration Statement on Form S-1, filed with the U.S. Securities and Exchange Commission (the “SEC”), File Number 333-296609 under the Securities Act of 1933, as amended (the “Securities Act”).

WHEREAS, the Purchaser has agreed to purchase an aggregate of 275,000 Shares (the “Private Placement Shares”).

…

EX-10.3·8-K·CIK 2137777·ACC 0001193125-26-303344·Filed Jul 14, 2026, 16:58 ET